These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34258542)

  • 21. Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder.
    Lambregts AP; Nieuwhof-Leppink AJ; Klijn AJ; Schroeder RPJ
    J Pediatr Urol; 2022 Jun; 18(3):351.e1-351.e8. PubMed ID: 35283021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction.
    Sager C; Sanmartino M; Burek C; Gomez YR; Vazquez Patiño M; Weller S; Ruiz J; Lopez Imizcoz F; Tessi C; Szklarz T; Corbetta JP
    J Pediatr Urol; 2020 Oct; 16(5):655.e1-655.e6. PubMed ID: 32800710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
    Jiang YH; Kuo HC
    Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adult T-cell leukemia-lymphoma in a patient with HTLV-I/II associated myelopathy.
    Freitas V; Gomes I; Bittencourt A; Fernandes D; Melo A
    Arq Neuropsiquiatr; 1997 Jun; 55(2):325-8. PubMed ID: 9629396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA.
    Al Taweel W; Alzyoud KM
    Urol Ann; 2015; 7(3):320-4. PubMed ID: 26229318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infection.
    Santos SB; Oliveira P; Luna T; Souza A; Nascimento M; Siqueira I; Tanajura D; Muniz AL; Glesby MJ; Carvalho EM
    J Med Virol; 2012 Nov; 84(11):1809-17. PubMed ID: 22997085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anatomical location and number of injection sites of intravesical OnabotulinumtoxinA for females with refractory idiopathic overactive bladder: A scoping review.
    Kelsey E; Wynn J; Holmes A; McLeod K
    Neurourol Urodyn; 2024 Mar; 43(3):553-564. PubMed ID: 38225733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.
    Wang CC; Lee CL; Kuo HC
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
    Jiang YH; Liao CH; Tang DL; Kuo HC
    PLoS One; 2014; 9(8):e105989. PubMed ID: 25148378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP.
    Nagai M; Yamano Y; Brennan MB; Mora CA; Jacobson S
    Ann Neurol; 2001 Dec; 50(6):807-12. PubMed ID: 11761481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human T-lymphotropic virus 1 (HTLV-1)-associated lichenoid dermatitis induced by CD8+ T cells in HTLV-1 carrier, HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T-cell leukemia/lymphoma.
    Tokura Y; Ito T; Kawakami C; Sugita K; Kasuya A; Tatsuno K; Sawada Y; Nakamura M; Shimauchi T
    J Dermatol; 2015 Oct; 42(10):967-74. PubMed ID: 26077665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
    Yokoyama O; Honda M; Yamanishi T; Sekiguchi Y; Fujii K; Nakayama T; Mogi T
    Int J Urol; 2020 Mar; 27(3):227-234. PubMed ID: 31957922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
    Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
    BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study.
    El-Dakhakhny AS; El-Karamany TM; El-Atrebi M; Gharib T
    Arab J Urol; 2019; 17(2):143-149. PubMed ID: 31285927
    [No Abstract]   [Full Text] [Related]  

  • 36. Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection.
    Silva MT; Harab RC; Leite AC; Schor D; Araújo A; Andrada-Serpa MJ
    Clin Infect Dis; 2007 Mar; 44(5):689-92. PubMed ID: 17278060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].
    Henriet B; Roumeguère T
    Rev Med Brux; 2015; 36(1):29-37. PubMed ID: 25856969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder.
    Carneiro Neto JA; Santos SB; Orge GO; Tanajura D; Passos L; Oliveira CJ; Andrade R; Melo CG; Barroso U; Carvalho EM
    Braz J Infect Dis; 2018; 22(2):79-84. PubMed ID: 29462596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
    Jiang YH; Ong HL; Kuo HC
    Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
    Gessain A; Mahieux R
    Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.